Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

被引:8
|
作者
Rao, Prakruti S. [1 ]
Modi, Nisha [2 ,3 ]
Nguyen, Nam-Tien Tran [4 ]
Vu, Dinh Hoa [4 ]
Xie, Yingda L. [2 ,3 ]
Gandhi, Monica [5 ]
Gerona, Roy [6 ]
Metcalfe, John [7 ,8 ]
Heysell, Scott K. [1 ]
Alffenaar, Jan-Willem C. [9 ,10 ,11 ]
机构
[1] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA USA
[2] Rutgers State Univ, Global TB Inst, Newark, NJ USA
[3] Rutgers State Univ, Dept Med, Newark, NJ USA
[4] Hanoi Univ Pharm, Natl Drug Informat & Adverse Drug React Monitorin, Hanoi, Vietnam
[5] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Maternal Fetal Med Div, San Francisco, CA USA
[7] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA USA
[8] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA USA
[9] Univ Sydney, Pharm Sch, Pharm Bldg A15,Sci Rd, Sydney, NSW 2006, Australia
[10] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[11] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia
基金
美国国家卫生研究院;
关键词
DRIED BLOOD SPOTS; RESISTANT TUBERCULOSIS; ARKANSAS METHOD; LEVOFLOXACIN PHARMACOKINETICS; ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; ISONIAZID TREATMENT; URINE COLORIMETRY; COLOR TEST; LC-MS/MS;
D O I
10.1007/s40262-023-01220-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveQuantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treatment failure or toxicity due to individual variability in pharmacokinetics. Traditionally, serum or plasma samples have been used for drug monitoring, which only poses collection and logistical challenges in high-tuberculosis burden/low-resourced areas. Less invasive and lower cost tests using alternative biomatrices other than serum or plasma may improve the feasibility of therapeutic drug monitoring.MethodsA systematic review was conducted to include studies reporting anti-tuberculosis drug concentration measurements in dried blood spots, urine, saliva, and hair. Reports were screened to include study design, population, analytical methods, relevant pharmacokinetic parameters, and risk of bias.ResultsA total of 75 reports encompassing all four biomatrices were included. Dried blood spots reduced the sample volume requirement and cut shipping costs whereas simpler laboratory methods to test the presence of drug in urine can allow point-of-care testing in high-burden settings. Minimal pre-processing requirements with saliva samples may further increase acceptability for laboratory staff. Multi-analyte panels have been tested in hair with the capacity to test a wide range of drugs and some of their metabolites.ConclusionsReported data were mostly from small-scale studies and alternative biomatrices need to be qualified in large and diverse populations for the demonstration of feasibility in operational settings. High-quality interventional studies will improve the uptake of alternative biomatrices in guidelines and accelerate implementation in programmatic tuberculosis treatment.
引用
收藏
页码:375 / 398
页数:24
相关论文
共 50 条
  • [21] Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review
    Carland, Jane E.
    Carland, David J.
    Brett, Jonathan
    Stocker, Sophie L.
    Roberts, Darren M.
    Day, Richard O.
    Laba, Tracey-Lea
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (09) : 2038 - 2066
  • [22] Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range
    Eichentopf, L.
    Hiemke, C.
    Hefner, G.
    Schoretsanitis, G.
    Kuzin, M.
    Zernig, G.
    Havemann-Reinecke, U.
    Gerlach, M.
    Conca, A.
    Gruender, G.
    Hart, X.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S507 - S508
  • [23] Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range
    Eichentopf, L.
    Hiemke, C.
    Conca, A.
    Engelmann, J.
    Gerlach, M.
    Havemann-Reinecke, U.
    Hefner, G.
    Florio, V
    Kuzin, M.
    Lieb, K.
    Reis, M.
    Riemer, T. G.
    Seretti, A.
    Schoretsanitis, G.
    Zernig, G.
    Gruender, G.
    Hart, X. M.
    PHARMACOPSYCHIATRY, 2022, 55 (03) : 164 - 165
  • [24] THERAPEUTIC DRUG-MONITORING AND PHARMACOKINETIC DOSE PREDICTION METHODS
    OELLERICH, M
    WIENER KLINISCHE WOCHENSCHRIFT, 1992, 104 : 12 - 15
  • [25] Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review
    Ye, Zhi-Kang
    Li, Can
    Zhai, Suo-Di
    PLOS ONE, 2014, 9 (06):
  • [27] Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study
    Cuvelier, Elodie
    Khazri, Houda
    Lecluse, Cloe
    Hennart, Benjamin
    Amad, Ali
    Roche, Jean
    Tod, Michel
    Vaiva, Guillaume
    Cottencin, Olivier
    Odou, Pascal
    Allorge, Delphine
    Decaudin, Bertrand
    Simon, Nicolas
    PHARMACEUTICALS, 2024, 17 (01)
  • [28] Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment
    Anderson, Ginger
    Vinnard, Christopher
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (10): : 1206 - 1214
  • [29] Therapeutic Drug Monitoring in the Treatment of Tuberculosis: Minimizing the Risks of ADRs
    Iqbal, M. S.
    Iqbal, M. Z.
    Bahari, M. B.
    Iqbal, M. W.
    DRUG SAFETY, 2014, 37 (10) : 883 - 884
  • [30] Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
    Zuur, Marlanka A.
    Bolhuis, Mathieu S.
    Anthony, Richard
    den Hertog, Alice
    van der Laan, Tridia
    Wilffert, Bob
    de Lange, Wiel
    van Soolingen, Dick
    Alffenaar, Jan-Willem C.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (05) : 509 - 521